The Qatar Cardiovascular Biorepository (QCBio) consists of plasma and DNA of Qatari patients with coronary heart disease (CHD) and age, gender, and ethnicity-matched controls. CHD cases include patients with acute coronary syndromes (myocardial infarction, unstable angina) identified in the cardiac catheterization laboratory/coronary care unit. Controls include blood donors who have no history of CHD.
The resource is funded by the Qatar National Research Foundation (QNRF) to enable validation of biomarkers to assess CHD risk, response to therapy, and prognosis. QCBio will also allow genomic and proteomic studies of CHD and response to drug therapy (pharmacogenetics and pharmacoproteomics).